GlaxoSmithKline: Respiratory Tract Infections trials

The registry lists 21 Respiratory Tract Infections studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 14Phase 3 4Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in IndiaCompletedNCT04600752Phase 4Results posted
• A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy InfantsCompletedNCT02447432Phase 3Results posted
• Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive DiseaseCompletedNCT00861380Phase 3Results posted
• Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European AncestryCompletedNCT06577597Phase 1
• An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and FluWithdrawnNCT02730364Phase 3
• A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral SolutionCompletedNCT02688361Phase 1
• An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and FluWithdrawnNCT02678234Phase 3
• Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy VolunteersCompletedNCT02257398Phase 1
• A Single Oral Escalating Dose Study of GSK2140944 in Healthy VolunteersCompletedNCT02202187Phase 1
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult SubjectsCompletedNCT02169583Phase 1
• A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male SubjectsCompletedNCT02000765Phase 1
• Bioequivalence Study of an Amoxicillin-ClavulanicCompletedNCT01772238Phase 1
• Bioequivalence Study of Cephalexin Tablets 1gCompletedNCT01767584Phase 1
• Bioequivalence Study of Cephalexin Suspension 250CompletedNCT01767571Phase 1
• Bioequivalence Study of Cephalexin Suspension 125CompletedNCT01767532Phase 1
• This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult SubjectsCompletedNCT01706315Phase 1
• Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV DosesCompletedNCT01615796Phase 1
• Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review StudyCompletedNCT01353768
• A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United KingdomTerminatedNCT01292213
• A Three-Part Study Of GSK580416 In Healthy SubjectsCompletedNCT00427141Phase 1
• Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent PatientsCompletedNCT00354965Phase 1